CD33 antibodies and methods of using the same to treat cancer
AssigneeMemorial Sloan Kettering Cancer Center
InventorsNai-Kong V. Cheung, Sayed Shahabuddin Hoseini, Mahiuddin Ahmed
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CDS 3 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or a CDS 3-associated cancer in a subject in need thereof.
Claims22
An antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein
- (a) the VH comprises a VH-CDR1 sequence of GYSFTDYN (SEQ ID NO:
- 154), a VH-CDR2 sequence of IDPYKGGT (SEQ ID NO:
- 155), and a VH-CDR3 sequence of AREMITAYYFDY (SEQ ID NO:
- 156);
- and
- (b) the VL comprises a VL-CDR1 sequence of QDINKY (SEQ ID NO:
- 157), a VL-CDR2 sequence of YAS (SEQ ID NO:
- 158), and a VL-CDR3 sequence of LQYDNLLT (SEQ ID NO:
- 159), optionally wherein
- the antibody or antigen binding fragment binds to the IgC2 domain of CD33, or
- the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody, or the antigen binding fragment is selected from the group consisting of Fab, F(ab′)2, Fab′, scFv, and Fv
- and optionally wherein the bispecific antibody binds to T cells, B-cells, myeloid cells, plasma cells, or mast-cells, or wherein the bispecific antibody or antigen binding fragment binds to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCR gamma/delta, NKp46, KIR, or a small molecule DOTA hapten.
An antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein:
- (a) the VH comprises an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, and SEQ ID NO:
- 133;
- and
- (b) the VL comprises an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, and SEQ ID NO:
- 13, optionally wherein
- the antibody or antigen binding fragment binds to the IgC2 domain of CD33, or
- the antibody or antigen binding fragment is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody, or the antigen binding fragment is selected from the group consisting of Fab, F(ab′)2, Fab′, scFv, and Fv, or
- wherein the bispecific antibody or antigen binding fragment binds to T cells, B-cells, myeloid cells, plasma cells, or mast-cells, CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCR gamma/delta, NKp46, KIR, or a small molecule DOTA hapten or
- wherein the bispecific antibody comprises an amino acid sequence selected from any one of SEQ ID NOs. 30-113 or 142-153.
An antibody comprising a heavy chain (HC) amino acid sequence comprising SEQ ID NO:
- 16, SEQ ID NO:
- 20, SEQ ID NO:
- 22, SEQ ID NO:
- 136, SEQ ID NO:
- 139, SEQ ID NO:
- 141, and a light chain (LC) amino acid sequence comprising SEQ ID NO:
- 14, SEQ ID NO:
- 18, SEQ ID NO:
- 24, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, SEQ ID NO:
- 134, SEQ ID NO:
- 138, SEQ ID NO:
- 140, optionally wherein
- the antibody binds to the IgC2 domain of CD33, or
- the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody,
- and optionally wherein the bispecific antibody binds to T cells, B-cells, myeloid cells, plasma cells, or mast-cells, or wherein the bispecific antibody binds to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCR gamma/delta, NKp46, KIR, or a small molecule DOTA hapten.
Dependencies are inferred from the claim text.